Title |
Biomarker-based adaptive trials for patients with glioblastoma—lessons from I-SPY 2
|
---|---|
Published in |
Neuro-Oncology, July 2013
|
DOI | 10.1093/neuonc/not088 |
Pubmed ID | |
Authors |
Brian M Alexander, Patrick Y Wen, Lorenzo Trippa, David A Reardon, Wai-Kwan Alfred Yung, Giovanni Parmigiani, Donald A Berry |
Abstract |
The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Bosnia and Herzegovina | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 5% |
Unknown | 41 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 21% |
Student > Ph. D. Student | 5 | 12% |
Other | 4 | 9% |
Student > Bachelor | 4 | 9% |
Student > Postgraduate | 3 | 7% |
Other | 10 | 23% |
Unknown | 8 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 40% |
Agricultural and Biological Sciences | 4 | 9% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Mathematics | 2 | 5% |
Engineering | 2 | 5% |
Other | 5 | 12% |
Unknown | 11 | 26% |